APA (7th ed.) Citation

Spigel, D. R., Hainsworth, J. D., Joseph, M. J., Shipley, D. L., Hagan, M. K., Thompson, D. S., . . . Burris, H. A. 3. (2018). Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer (0008543X), 124(9), 1982. https://doi.org/10.1002/cncr.30986

Chicago Style (17th ed.) Citation

Spigel, David R., John D. Hainsworth, Mathew J. Joseph, Dianna L. Shipley, M. Kelly Hagan, Dana S. Thompson, III Burris, F. Anthony Greco, and Howard A 3rd Burris. "Randomized Phase 2 Trial of Pemetrexed, Pemetrexed/bevacizumab, and Pemetrexed/carboplatin/bevacizumab in Patients with Stage IIIB/IV Non-small Cell Lung Cancer and an Eastern Cooperative Oncology Group Performance Status of 2." Cancer (0008543X) 124, no. 9 (2018): 1982. https://doi.org/10.1002/cncr.30986.

MLA (9th ed.) Citation

Spigel, David R., et al. "Randomized Phase 2 Trial of Pemetrexed, Pemetrexed/bevacizumab, and Pemetrexed/carboplatin/bevacizumab in Patients with Stage IIIB/IV Non-small Cell Lung Cancer and an Eastern Cooperative Oncology Group Performance Status of 2." Cancer (0008543X), vol. 124, no. 9, 2018, p. 1982, https://doi.org/10.1002/cncr.30986.